Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)
Abstract
Hospital-acquired pneumonia (HAP) and ventilatorassociated pneumonia (VAP) are the most common hospitalacquired infections in China.The difficulty in diagnosis and treatment of HAP/VAP leads to high mortality.In China, it has been nearly two decades since the initial "Guideline for the Diagnosis and Treatment of Hospital-acquired Pneumonia (draft)" was published in 1999 (1).Afterwards, a number of guidelines for HAP/VAP have been published or updated at home and abroad (2-10).The definitions of HAP/VAP have been changing as more and more relevant researches available highlighting greater details.Moreover, there are growing evidence in the epidemiology, etiology, clinical diagnosis and treatment of HAP/VAP, especially
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.